These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 28118080

  • 1. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
    Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF.
    Cell Cycle; 2017 Mar 19; 16(6):499-507. PubMed ID: 28118080
    [Abstract] [Full Text] [Related]

  • 2. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
    Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF, Chen X.
    Hepatology; 2016 Jun 19; 63(6):1900-13. PubMed ID: 26910791
    [Abstract] [Full Text] [Related]

  • 3. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M.
    Gastroenterology; 2011 Mar 19; 140(3):1071-83. PubMed ID: 21147110
    [Abstract] [Full Text] [Related]

  • 4. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, Zheng G, Qiu Z.
    Toxicol Appl Pharmacol; 2019 Feb 15; 365():51-60. PubMed ID: 30625338
    [Abstract] [Full Text] [Related]

  • 5. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
    Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, Ribback S, Simile MM, Pascale RM, Dombrowski F, Evert M, Semenkovich CF, Chen X, Calvisi DF.
    J Hepatol; 2016 Feb 15; 64(2):333-341. PubMed ID: 26476289
    [Abstract] [Full Text] [Related]

  • 6. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L.
    Gut; 2020 Jan 15; 69(1):177-186. PubMed ID: 30954949
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
    Ribback S, Che L, Pilo MG, Cigliano A, Latte G, Pes GM, Porcu A, Pascale RM, Li L, Qiao Y, Dombrowski F, Chen X, Calvisi DF.
    Cell Cycle; 2018 Jan 15; 17(12):1496-1512. PubMed ID: 29965794
    [Abstract] [Full Text] [Related]

  • 10. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
    Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, Wang G, Qiu Z.
    Food Funct; 2019 Jun 19; 10(6):3410-3420. PubMed ID: 31123744
    [Abstract] [Full Text] [Related]

  • 11. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
    Mo Y, Wu Y, Li X, Rao H, Tian X, Wu D, Qiu Z, Zheng G, Hu J.
    Eur J Pharmacol; 2020 Jan 15; 867():172788. PubMed ID: 31712058
    [Abstract] [Full Text] [Related]

  • 12. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
    Zhang C, Sheng L, Yuan M, Hu J, Meng Y, Wu Y, Chen L, Yu H, Li S, Zheng G, Qiu Z.
    Toxicol Appl Pharmacol; 2020 Apr 01; 392():114918. PubMed ID: 32045588
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
    Li J, Huang Q, Long X, Zhang J, Huang X, Aa J, Yang H, Chen Z, Xing J.
    J Hepatol; 2015 Dec 01; 63(6):1378-89. PubMed ID: 26282231
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation.
    Cigliano A, Simile MM, Vidili G, Pes GM, Dore MP, Urigo F, Cossu E, Che L, Feo C, Steinmann SM, Ribback S, Pascale RM, Evert M, Chen X, Calvisi DF.
    Medicina (Kaunas); 2024 Jul 18; 60(7):. PubMed ID: 39064589
    [Abstract] [Full Text] [Related]

  • 17. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
    Liang Y, Feng Y, Zong M, Wei XF, Lee J, Feng Y, Li H, Yang GS, Wu ZJ, Fu XD, Feng GS.
    Hepatology; 2018 May 18; 67(5):1807-1822. PubMed ID: 29152756
    [Abstract] [Full Text] [Related]

  • 18. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.
    Li L, Wang C, Calvisi DF, Evert M, Pilo MG, Jiang L, Yuneva M, Chen X.
    PLoS One; 2013 May 18; 8(9):e75104. PubMed ID: 24069385
    [Abstract] [Full Text] [Related]

  • 19. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
    Qiu Z, Zhang C, Zhou J, Hu J, Sheng L, Li X, Chen L, Li X, Deng X, Zheng G.
    Mol Carcinog; 2019 Jan 18; 58(1):31-41. PubMed ID: 30182439
    [Abstract] [Full Text] [Related]

  • 20. Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients.
    Wang MD, Wu H, Fu GB, Zhang HL, Zhou X, Tang L, Dong LW, Qin CJ, Huang S, Zhao LH, Zeng M, Wu MC, Yan HX, Wang HY.
    Hepatology; 2016 Apr 18; 63(4):1272-86. PubMed ID: 26698170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.